Palantir is a sell due to high dilution, insider selling, and valuation concerns despite strong growth projections.
Source Post
3 Undervalued Stocks to Buy (& 3 Massively Overhyped!) Before March 2026 Ends
Everything MoneyMar 9, 2026
The creator analyzes HIMS, a company that has seen a significant stock price drop due to regulatory issues with weight loss drugs and lawsuits from Novo Nordisk. Despite these challenges, the creator notes that a majority of HIMS's business is unrelated to weight loss and is growing, with substantial cash reserves and international expansion plans. The analysis focuses on valuation and free cash flow to determine if HIMS presents a buying opportunity or is an overhyped stock.
Linked Mentions
Tickers discussed in this post
Tesla is a sell due to its extremely high P/E ratio, declining car sales, loss of EV market leadership to BYD, and brand risks.
HIMS is a potential opportunity despite legal and regulatory headwinds, as its core business is growing and it has strong cash reserves.